Market closed

Ikena Oncology/$IKNA

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Ikena Oncology

Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.

Ticker

$IKNA

Sector

Health Care

Trading on

NASDAQ

Industry

Pharmaceuticals

Headquarters

Boston, United States

Employees

Website

ikenaoncology.com

Ikena Oncology Metrics

BasicAdvanced

$73M

-

-$1.24

0.49 -

Price and volume

Market cap

$73M

Beta

0.49

52-week high

$1.94

52-week low

$1.22

Average daily volume

331K

Financial strength

Current ratio

15.317

Quick ratio

14.939

Long term debt to equity

3.331

Total debt to equity

6.253

Management effectiveness

Return on assets (TTM)

-22.06%

Return on equity (TTM)

-37.08%

Valuation

Price to revenue (TTM)

110.356

Price to book

0.54

Price to tangible book (TTM)

0.54

Price to free cash flow (TTM)

-1.176

Growth

Revenue change (TTM)

-95.28%

Earnings per share change (TTM)

-23.45%

3-year revenue growth (CAGR)

-60.67%

3-year earnings per share growth (CAGR)

-27.05%

What the Analysts think about Ikena Oncology

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Ikena Oncology stock.

Ikena Oncology Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

Ikena Oncology Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Ikena Oncology News

AllArticlesVideos

Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement

GlobeNewsWire·3 weeks ago

Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement

GlobeNewsWire·3 weeks ago

Ikena Oncology Reports Third Quarter 2024 Financial Results

GlobeNewsWire·2 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $IKNA

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Ikena Oncology stock?

Ikena Oncology (IKNA) has a market cap of $73M as of January 15, 2025.

What is the P/E ratio for Ikena Oncology stock?

The price to earnings (P/E) ratio for Ikena Oncology (IKNA) stock is 0 as of January 15, 2025.

Does Ikena Oncology stock pay dividends?

No, Ikena Oncology (IKNA) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Ikena Oncology dividend payment date?

Ikena Oncology (IKNA) stock does not pay dividends to its shareholders.

What is the beta indicator for Ikena Oncology?

Ikena Oncology (IKNA) has a beta rating of 0.49. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.